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Abstract
Intravenous immunoglobulin (IVIg) is a blood-derived product, used for the treatment of immunodeficiency and
autoimmune diseases. Since a range of immunotherapies have recently been proposed as a therapeutic strategy for
Parkinson’s disease (PD), we investigated the effects of an IVIg treatment in a neurotoxin-induced animal model of
PD. Mice received four injections of MPTP (15 mg/kg) at 2-hour intervals followed by a 14-day IVIg treatment, which
induced key immune-related changes such as increased regulatory T-cell population and decreased CD4+/CD8+
ratio. The MPTP treatment induced significant 80% and 84% decreases of striatal dopamine concentrations
(P< 0.01), as well as 33% and 40% reductions in the number of nigral dopaminergic neurons (P< 0.001) in controls
and IVIg-treated mice, respectively. Two-way analyses of variance further revealed lower striatal tyrosine hydroxylase
protein levels, striatal homovanillic acid concentrations and nigral dopaminergic neurons (P< 0.05) in IVIg-treated
animals. Collectively, our results fail to support a neurorestorative effect of IVIg on the nigrostriatal system in the
MPTP-treated mice and even suggest a trend toward a detrimental effect of IVIg on the dopaminergic system.
These preclinical data underscore the need to proceed with caution before initiating clinical trials of IVIg in PD
patients.
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Background
Central and peripheral activation of the innate and adap-
tive immune systems have been associated with neuro-
degenerative diseases such as Parkinson’s disease (PD).
Elevated concentrations of cytokines, such as TNFα,
IL-1β, IL-6, TGFβ (transforming growth factor-beta) and
IFNγ have been reported in mouse models of dopamin-
ergic (DAergic) denervation [1,2] as well as in the sub-
stantia nigra pars compacta (SNpc) and striatum of PD
patients [2-6]. Similarly, increased concentrations of
macrophage migration inhibition factor, IL-2, IL-6, TNFα
and TNFα receptor-1 have been measured in the blood
of PD patients [7-13]. Migration of both CD4+ (helper)
and CD8+ (cytotoxic) T-lymphocytes have been identi-
fied within the SNpc of PD patients and further asso-
ciated with nigrostriatal denervation in a mouse model
of PD through a CD4+ T-cell-dependent Fas/Fas ligand
(FasL) cytotoxic pathway [14]. Immunological abnormal-
ities observed in PD patients and animal models suggest
an overall disruption of the immune system in the dis-
ease, but their causal role is still highly debated. It
remains to be demonstrated whether immunological ab-
normalities are relevant therapeutic targets for neurode-
generative disorders.
Recently, intravenous immunoglobulin (IVIg) has been
proposed in the treatment of neurodegenerative diseases.
The safety and tolerability profiles of IVIg have justified
the initiation of phase II and phase III clinical trials in
Alzheimer’s disease (AD) patients and in individuals
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suffering from mild cognitive impairments (reviewed in
[15]). IVIg is a therapeutic preparation of over 98%
human IgG purified from the plasma of thousands of
healthy donors [16-19]. Besides its routine use for a
growing number of autoimmune diseases, beneficial
effects of IVIg have also been reported in immune-
mediated neurological diseases such as chronic inflam-
matory demyelinating polyneuropathy, Guillain–Barré
syndrome, multiple sclerosis and multifocal motor neur-
opathy (reviewed in [20-23]).
Although the mechanisms of action of IVIg remain
only partially understood, anti-inflammatory and immu-
nomodulatory effects have been described both in vitro
and in vivo [24-28]. In theory, some of these functions
could correct key immunologic defects described in PD.
For example, in humans, IVIg treatments decrease
plasma levels of TGFβ, IL-1β, IL-6, IL-8, IFNγ and TNFα
[29,30], all shown to be upregulated in PD. In vitro, IVIg
has also been reported to decrease phagocytosis in
microglia, to modulate transendothelial cell migration,
adhesion and rolling, and to interfere with the Fas/FasL
cytotoxic pathway [31-34]. More recently, increased hip-
pocampal neurogenesis following IVIg treatment has been
reported in a mouse model of AD [35]. Furthermore,
active and passive immunization against α-synuclein
(α-syn), the main component of the neuronal cytoplas-
mic inclusions found in PD [36,37], has been shown
to reduce neuropathology and behavioral deficits in an
α-syn transgenic mouse model [38,39]. In line with these
latter observations, antibodies specific to α-syn have re-
cently been isolated from IVIg [40], further suggesting
a potential clinical application for the use of IVIg to
achieve passive immunization in PD.
Current therapies in PD are mainly symptomatic, and
no drugs have ever obtained a label of disease modifica-
tion or neuroprotection from health agencies [41,42]. In
light of the existing data for the benefits of IVIg in auto-
immune and neurological diseases, we undertook to in-
vestigate whether such an approach could also benefit
PD patients. To test this hypothesis, we evaluated
whether IVIg could lead to the neurorestoration of the
DAergic system after a nigrostriatal lesion. We used a
post-MPTP paradigm where the IVIg treatment was
delivered after the MPTP insult. This approach avoids
unwanted interference of IVIg with MPTP toxicokinetics
and is more representative of the typical clinical setting




All biochemical reagents were purchased from J.T. Baker
(Phillipsburg, NJ, USA) unless otherwise specified.
Animals, MPTP administration and IVIg treatment
Eight-week-old C57BL6J males (22 to 27 g), purchased
from Charles River Laboratories (Montréal, QC, Canada)
were housed three per cage with free access to food and
water. All procedures were approved by the Animal Re-
search Committee of Laval University.
Animals were injected intraperitoneally with MPTP
neurotoxin following a standard acute protocol [43-45]
and were sacrificed 14 days later (Figure 1). On day 0,
the mice received four injections of an MPTP–HCl solu-
tion (15 mg free base/kg; Sigma-Aldrich, Oakville, ON,
Canada) freshly dissolved in 0.9% saline, at 2-hour inter-
vals. To avoid that the pharmacologic intervention under
study alters MPTP toxicokinetics, Jackson-Lewis and
Przedborski suggested delaying the beginning of the
treatment for at least 8 hours after the last MPTP injec-
tion [43]. An IVIg treatment posology of 0.4 g × kg-1 ×
week-1 has shown efficacy in a recent AD clinical trial
[46]. However, the mouse metabolism is faster than that
of humans, as exemplified by the IVIg half-life of 89
hours in mice (unpublished data) instead of 35 days in
Figure 1 Experimental design. Mice received four injections of the
neurotoxin MPTP (15 mg/kg; MPTP group) or an equivalent volume
of saline (vehicle group) every 2 hours on day 0. Twenty hours after
the last injection, mice received intraperitoneal injections of 30 mg
intravenous immunoglobulin (IVIg) or an equivalent volume of 0.2 M
glycine pH 4.0 (control group) on the first day (bolus) and 10 mg
daily (maintenance dose) for the remaining 13 days. Mice were
sacrificed on day 15 by intracardiac perfusion under deep
anesthesia.
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humans [17]. To match the human dosage as closely as
possible, we thus selected a dose of 0.4 g × kg-1 × day-1.
To quickly reach therapeutic concentrations, mice
(n= 15 or 16/group) received a bolus dose of 30 mg IVIg
(~1.2 g/kg from a 100 mg/ml human IgG solution,
diluted in 0.2 M glycine pH 4.25 – Gammunex™; Grifols,
Mississauga, ON, Canada) or an equivalent volume of
glycine (0.2 M, pH 4.25) 20 hours following the last
MPTP injection. For the remaining 13 days, animals
were injected daily with 10 mg/day (~0.4 g × kg-1 × day-1)
IVIg or glycine (maintenance dose) for a total treatment
duration of 14 days. The animals were sacrificed 2 weeks
after the last MPTP injection to probe for a neurorestora-
tive effect of IVIg on the ongoing MPTP-induced neuro-
degeneration of the DAergic system.
Tissue preparation for postmortem analyses
Terminal intracardiac perfusion was performed under
deep anesthesia (ketamine/xylazine). After transcardiac
administration of 50 ml PBS buffer (Bioshop Canada
Inc., Burlington, ON, Canada) containing protease and
phosphatase inhibitors (SigmaFAST Protease Inhibitor
Tablets (Sigma-Aldrich) with 50 mM sodium fluoride
and 1 mM sodium pyrophosphate), both spleen and
brain were collected. Brain hemispheres were separated:
the striatum was dissected from the rostral section of
the right hemisphere, snap-frozen on dry ice and stored
at −80°C. The caudal section was post-fixed in 4% paraf-
ormaldehyde pH 7.4 and sliced with a freezing micro-
tome (coronal brain sections of 25 μm). The left
hemisphere was snap-frozen in 2-methyl-butane and
stored at −80°C for cryostat coronal brain sections
(12 μm). Splenocytes were recovered from the spleen fol-
lowing mechanical disaggregation, frozen at −80°C in a
cryoprotective medium (Iscove’s Modified Dulbecco’s
Medium supplemented with 20% fetal bovine serum and




Cell surface marker expression on splenocytes were ana-
lyzed using AF647-conjugated anti-CD3 (clone 17A2;
BD Biosciences, Mississauga, ON, Canada), eFluor 780-
conjugated anti-B220 (clone RM4-5; BD Biosciences),
PE-Cy7-conjugated anti-CD4 (clone GK1.5; eBioscience,
San Diego, CA, USA), eFluor 450-conjugated anti-CD8a
(clone 53–6.7; eBioscience), APC-conjugated anti-
CD11b (clone M1/70; BD Biosciences), FITC-conjugated
anti-Gr1 (LY-6 G clone RB6-8C5; eBioscience) or rele-
vant isotypic controls in PBS–1% BSA. For human IgG
detection, splenocytes were labeled with PE-conjugated
anti-CD45 and FITC-conjugated anti-human IgG. For
regulatory T-lymphocyte analyses, splenocytes were
stained on ice for 30 minutes with PE-conjugated anti-
CD25 (clone PC61.5; eBioscience) and APC-conjugated
anti-CD4 (clone RM4-5; BD Bioscience) followed by
permeabilization and fixation using the Foxp3 staining
buffer (eBioscience) and staining with eFluor450-
conjugated anti-Foxp3 (clone FJK-16s; eBioscience) fol-
lowing the manufacturer’s instructions. Cells were
acquired and analyzed using a CyFlow ML (Partec,
Swedesboro, NJ, USA) cytometer and FCS express soft-
ware (De Novo Software, Los Angeles, CA, USA).
ELISPOT analyses
To determine whether the injection of IVIg triggered an
anti-human IgG immune response, an ELISPOT test
was performed. Briefly, splenocytes were unfrozen,
washed, counted, plated on human IgG-coated wells
(MultiscreenW HTS filter plate; Millipore Corporation,
Billerica, MA, USA) blocked with 5% fetal bovine serum
and left immobile for 16 hours at 37°C, 10% CO2 for
antibody secretion. After washing the cells, anti-human
specific mouse immunoglobulins were detected using a
horseradish peroxidase-conjugated anti-mouse IgG (heavy
and light chain specific; Jackson ImmunoResearch Labora-
tories Inc., West Grove, PA, USA) and TrueBlue™ Peroxy-
dase Substrate (KPL, Mandel Scientific, Gaithersburg,
MD, USA). Each spot was counted under a dissection
microscope and considered a single anti-human specific B




ELISA and Western immunoblot analyses Each stri-
atum was homogenized in 8 volumes of lysis buffer per
milligram of tissue (150 mM NaCl, 10 mM Na2HPO4,
0.5% sodium dodecylsulfate, 0.5% sodium deoxycholate,
1% Triton X-100 containing Complete™ protease inhibi-
tors cocktail (Roche, Indianapolis, IN, USA), 10 μg/ml
pepstatin A and 1 mM each of sodium fluoride and so-
dium orthovanadate as phosphatase inhibitors) and was
sonicated three times for five 1-second pulses. The solu-
tion was centrifuged at 100,000×g for 20 minutes at 4°C,
and the supernatant was retrieved and kept at −80°C for
ELISA and immunoblotting. The protein concentration
was determined using a bicinchoninic acid assay (Pierce,
Rockford, IL, USA).
An ELISA specific to human IgG was utilized to de-
termine the striatal concentration of IVIg using goat
anti-human IgG Fc-specific antibodies (Jackson Immu-
noResearch Laboratories Inc.). For immunoblot analyses,
proteins (20 μg/samples) were heated at 95°C for 5 min-
utes in Laemmli’s loading buffer and separated by SDS-
PAGE on a 10% polyacryamide gel, before transferring
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to a polyvinylidene fluoride membrane (Immobilon-P™;
Millipore Corporation) that was blocked in 5% nonfat
dry milk, 0.5% BSA, 0.1% Tween 20 in PBS buffer as pre-
viously described [47]. Tyrosine hydroxylase (TH) pro-
tein was detected using rabbit anti-TH (1:5,000, #P40101;
Pel-Freez, Rogers, AR, USA) primary antibody followed
by horseradish peroxidase-labeled secondary antibody
and chemiluminescence reagents (Lumiglo Reserve; KPL)
as previously described [48]. Membranes were also probed
for β-actin (1:10,000; Applied Biological Materials Inc.,
Richmond, BC, Canada) as a control for protein load.
Band intensities were quantified using a KODAK Im-
aging Station 4000 MM Digital Imaging System (Molecu-
lar Imaging Software version 4.0.5f7; Carestream Health,
Rochester, NY, USA).
Catecholamine and indolamine quantification Ten
slices of 20 μm rostral striata were homogenized in 200
μl of 0.1 N perchloric acid (Mallinckrodt Baker, Phillips-
burg, NJ, USA) and centrifuged at 12,000×g for 10 min-
utes at 4°C. HPLC with electrochemical detection was
used to evaluate the concentration of dopamine (DA),
3,4-dihydroxyphenylacetic acid (DOPAC) and homova-
nillic acid (HVA) in striatal supernatant, as previously
described [48]. Briefly, 50 μl supernatant were injected
into the chromatograph consisting of a Waters 717 plus
autosampler automatic injector, a Waters 1525 binary
pump equipped with an Atlantis dC18 column, a Waters
2465 electrochemical detector, and a glassy carbon elec-
trode (Waters Ltd, Lachine, QC, Canada). The electro-
chemical detector was set at 10 nA. The mobile phase
consisted of 47.8 mM NaH2PO4, 0.9 m M sodium octyl
sulfate, 0.4 mM ethylenediamine tetraacetic acid, 2mM
NaCl and 8% (v/v) methanol at pH 2.9 and was delivered
at 0.8 ml/minute. Peaks were identified using Breeze
Software (Waters Ltd) and HPLC quantifications were
normalized to protein concentrations.
Dopamine transporter quantification
DA transporter (DAT) was evaluated with 3β-(4-125I-
iodophenyl) tropane-2-carboxylic acid isopropylester
(125I-RTI-121, 2,200 Ci/mmol; NEN-DuPont, Boston,
MA, USA), as previously described [45,49]. Slide-
mounted brain sections were preincubated at room
temperature for 30 minutes in phosphate buffer pH 7.4
followed by a 90-minute incubation with 20 pM 125I-
RTI-121. Nonspecific binding was determined in the
presence of 0.1 μM mazindol (Novartis Pharmaceuticals,
Dorval, QC, Canada). Sections were then washed with
phosphate buffer followed by distilled water, dried over-
night and exposed to Kodak BioMax film for 16 hours
(Sigma-Aldrich). Densitometry was quantified using the
ImageJ Analysis Software (National Institutes of Health,
USA). The average labeling for each area was calculated
from the mean of six adjacent brain sections from the
rostral striatum of a 1/10 series of the same animal.
Substantia nigra
Immunohistochemistry To visualize TH-positive neu-
rons of the SNpc, sections were first incubated for 30
minutes in 3% H2O2 and blocked with 5% normal goat
serum and 0.1% Triton in PBS for 30 minutes. After an
overnight incubation with an anti-TH antibody (1:5,000;
Pel-Freez), sections were washed three times in PBS and
incubated for 1 hour with biotin-conjugated anti-rabbit
antibody. After further washing, the sections were placed
in a solution containing ABC (Elite kit; Vector Labo-
ratories, Burlington, ON, Canada) for 1 hour at room
temperature. The bound peroxidase was revealed with
0.5 mg/ml DAB (Sigma-Aldrich) and 0.01% hydrogen
peroxide in 0.05 M Tris (pH 7.6). The reaction was
stopped by extensively washing the sections in PBS. The
sections were counterstained with cresyl violet, dehy-
drated and cover slipped. Photomicrographs were taken
with a Microfire 1.0 camera (Optronics, Goleta, CA, USA)
linked to an E800 Nikon 274 microscope (Nikon Inc.,
Québec, QC, Canada) using the imaging software Pic-
ture Frame.
Stereological counts of TH-positive and cresyl-violet-
stained cells The total number of TH-positive and TH-
negative neurons of the SNpc was quantified stereologi-
cally on seven sections of a 1/5 series, as previously
described [48-50]. Selected sections, at intervals of 125
μm, were counted in a blinded fashion by two independ-
ent investigators using Stereo Investigator software
(MicroBrightfield, Williston, VT, USA) integrated to an
E800 Nikon 274 microscope. After delineating the SNpc
at low magnification (4× objective) a point grid was
overlaid onto each section. Stained cells (TH-positive or
cresyl-violet stained) with a clearly defined and intact
nucleus were counted using the optical fractionator
method at higher magnification (20× objective). The
counting variables were as follows: distance between
counting frames, 150 μm×150 μm; counting frame size,
75 μm; guard zone thickness, 1 μm. Cells were counted
only if they did not intersect forbidden lines.
Statistical analyses
Statistical analyses were performed using the JMP soft-
ware (version 9.0.2; SAS Institute Inc., Cary, IL, USA)
and Prism 4.0c (GraphPad Software Inc., La Jolla, CA,
USA). A Bartlett test was first performed on all data to
verify equal variance. In cases of equal variance, statis-
tical differences were determined using one-way analysis
of variance (ANOVA) followed by post-hoc test (Tukey’s
or Dunnett’s) for comparison between groups. When
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variances were unequal, a Welch ANOVA followed with
Dunnett’s multiple comparison test was employed. If a
Gaussian distribution could not be assumed, the Krus-
kal–Wallis nonparametric test was used followed by
Dunn's post-test. The survival curves were compared
using the log-rank test. To evaluate the overall effects of
IVIg in both the vehicle and MPTP groups, two-way
ANOVAs were also performed.
Results
Health status and IVIg treatment
Weight loss and mortality is commonly observed in the
acute MPTP protocol, particularly shortly after injec-
tions of the toxin [43]. In this study, MPTP administra-
tion led to the death of 5/31 mice between days 4 and 5
after toxin injection (Figure 2A): one mouse in the
MPTP-control group (n= 15) and four of the MPTP-
IVIg-treated animals (n= 16). MPTP-induced lethality
was thus significantly higher in the MPTP-IVIg group.
These animals were excluded from all postmortem ana-
lyses. An increase in weight loss, paralleling the mortal-
ity rate, was also observed in surviving animals from the
MPTP-IVIg group (Figure 2B,C), specifically at day 2.
Despite the fact that IVIg alone did not lead to increased
lethality or weight loss in the vehicle group, the treat-
ment tended to potentiate the detrimental effect of
MPTP and thus impact the general health status of the
treated animals.
IVIg administration increases the proportion of the
regulatory T cells in the spleen
We next evaluated the effects of IVIg on the splenic
population of regulatory T cells (Tregs), which are
known to be upregulated by IVIg in patients and mouse
models of inflammatory disorders [51-54]. Indeed, Tregs
suppress immune activation and maintain immune
homeostasis and tolerance [55,56], while protecting
nigrostriatal afferents in an MPTP mouse model of PD
[57-59]. Our data revealed that repeated injections of
IVIg resulted in an increase in the percentage of splenic
Tregs. A 21.6% increase of CD25+/Foxp3+ Tregs in the
CD4+ population following IVIg treatment was observed,
but only in the vehicle group (Figure 3A,B; 7.55% vs.
9.17% CD25+/Foxp3+ gated on CD4+, vehicle-control
and vehicle-IVIg respectively). MPTP treatment also
induced a 26.1% increase in the relative Treg population
(Figure 3A,B; MPTP-control: 9.52% Treg), but the IVIg
treatment did not further increase the Treg population
in the MPTP group. We also evaluated the sub-
population of iCOS+CD4+ T cells (Figure 3), as they have
previously been associated with IVIg-induced regulation
of the central nervous system (CNS) inflammatory re-
sponse [54], but no significant effects were observed in
any of the treated groups. Granulocyte, monocyte,
Figure 2 Intravenous immunoglobulin injection increases
MPTP-related weight loss and lethality. Lethality and weight loss
rate were monitored throughout the experiment. (A) Mortality rate
induced by MPTP treatment was higher in the intravenous
immunoglobulin (IVIg) group. (B) Weight and (C) weight variation of
the animals excluding all the mice that died before the end of the
protocol. Data are presented as mean± standard error of the mean
of 12 to 15 animals. Statistical analysis: (A) log-rank test was
performed to compare survival curves, *P<0.05 MPTP-IVIg versus
vehicle groups. (B),(C) One-way analysis of variance followed by
Tukey’s multiple comparison test, #P<0.05 MPTP-IVIg versus vehicle-
IVIg group, ωP<0.05 MPTP-IVIg versus MPTP-control group.
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Figure 3 Intravenous immunoglobulin injection modulates the relative populations of T lymphocytes. Flow cytometry analyses on
splenocytes labeled for regulatory (CD4+, CD25+ and Foxp3+) iCOS+CD4+ (CD62L low, CD4+, iCOS+ and Foxp3+), helper (CD4+) and cytotoxic
(CD8+) T cells. (A) Representative plots showing regulatory T cell (Treg; upper panels, gated on CD4+ cells) iCOS+CD4+ (middle panels, gated on
CD4+/CD62L low cells) and CD4+/CD8+ (lower panels, gated on CD3+ cells) analyses. (B) Intravenous immunoglobulin (IVIg) induced a mild but
significant increase in Treg relative population but not in (C) iCOS+/Foxp3+ or (D) iCOS+ populations. IVIg treatment also decreased the (E) CD4
+/CD8+ cell ratio. (B) to (E) Results are presented as mean± standard error of the mean (10 to 15 animals). Statistical analysis: *P<0.05 versus
vehicle-control group, one-way analysis of variance (ANOVA), followed by Dunnett’s multiple comparison test, ∞P<0.05 IVIg versus control,
two-way ANOVA.
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B-lymphocyte and T-lymphocyte populations in the sple-
nocytes of all animals were also analyzed but no statis-
tical differences were observed between groups (data not
shown). However, IVIg injections also led to a significant
decrease in the CD4+/CD8+ T lymphocytes ratio in the
vehicle and MPTP groups compared with controls, re-
spectively (Figure 3).
Bioavailability of IVIg in brain and periphery
We further measured the bioavailability of IVIg in the
brain and spleen of IVIg-treated mice. Detectable amounts
of extracellular IVIg were present on splenic CD45+ leuko-
cytes as evaluated by flow cytometry (Figure 4A,B) with a
mean fluorescence intensity of 14.54 ± 0.32 in the IVIg
groups versus a baseline autofluorescence intensity of 6.72
± 0.21 for controls. Using a human specific anti-IgG
ELISA, we also determined that the concentrations of IVIg
in striatal homogenates were as high as 5.8 ± 0.2 and 5.5 ±
0.3 ng IVIg/mg tissue in the vehicle-IVIg and MPTP-IVIg
groups, respectively (Figure 4C). These data suggest that
detectable amounts of human IgG are present in the brain
and on the surface of circulating leukocytes after a 14-day
treatment with IVIg in this parkinsonian mouse model.
IVIg induces a minimal immune response
To determine whether repeated IVIg injections induced
an anti-human IgG specific adaptive immune response,
ELISPOT analyses were performed (n= 10 per group).
With this technique, we were able to assess the number
of splenocytes secreting a specific anti-human IgG anti-
body in control and IVIg groups, 14 days post MPTP.
Although there was a significant increase in the number
of splenic cells reactive to human IgG following IVIg ad-
ministration (two-way ANOVA, P < 0.05), it remained
very low. The amount of anti-human IgG specific cells
was below 4/100,000 splenocytes in all animals. The ab-
solute number of antibody secreting cells per spleen was
445 ± 173 and 154 ± 98 for the vehicle-IVIg and MPTP-
IVIg group (mean ± standard error of the mean) versus
34 ± 22 and 23 ± 12 for the vehicle-control and MPTP-
control groups. For comparison purposes, in mouse
models of autoimmune diseases, the reported absolute
number of antibody secreting cells to myeloperoxidase,
Figure 4 Detectable amounts of intravenous immunoglobulin in the brain and splenocytes of treated mice. Human IgG concentrations
were evaluated on splenocytes and in the striatum of intravenous immunoglobulin (IVIg) and control mice. (A) Representative flow cytometric
analyses and (B) mean fluorescence intensity (MFI) quantification of extracellular human IgG on CD45+ splenocytes. Note that the MFI of the
control groups is equivalent to isotypic control and autofluorescence (data not shown). (C) Concentrations of IVIg were measured in striatum
homogenates from intracardially perfused mice using a specific ELISA. (B),(C) Data presented as mean ± standard error of the mean of 12 to 15
animals, ***P<0.001 versus control groups, one-way analysis of variance followed by Tukey’s multiple comparison test.
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nucleolin and dsDNA are higher than 11,000, 17,000
and 33,000 specific cells/spleen, respectively [60,61].
Effects of MPTP and IVIg on the striatal components of
the dopaminergic system
As evaluated by HPLC quantification, MPTP induced
significant reductions in striatal concentrations of DA
and its metabolites DOPAC and HVA, reaching 80%,
49%, and 51%, respectively, in IVIg-untreated mice
(P < 0.01, one-way ANOVA; Figure 5). Similarly, 84%,
65%, and 56% decreases of DA, DOPAC and HVA were
observed in the striatum of the IVIg-MPTP mice com-
pared with IVIg-vehicle mice (Figure 5A,B,C). When
two-way ANOVAs were performed, the IVIg treatment
was associated with a significant decrease in HVA and
serotonin (Figure 5B,D) compared with control groups.
Therefore, catecholamine data point toward the absence
of a restorative effect of the IVIg treatment after the
MPTP-induced nigrostriatal lesion.
A comparable 71% decrease of 125RTI-121-specific
DAT binding in both controls and IVIg-treated MPTP
mice compared with vehicle mice was measured in the
striatum (Figure 6A,B), further supporting the lack of
beneficial effects of IVIg. Moreover, TH, the rate-
limiting enzyme in the catecholamine synthesis [62], was
quantified in the striatum using Western immunoblot
analysis. MPTP markedly depleted TH protein levels by
64% in both the MPTP-IVIg and MPTP-control groups
compared with their respective controls (Figure 6C,D).
IVIg treatment also led to a 16% decrease in TH protein
levels in animals not exposed to MPTP. Two-way ANO-
VAs further underscored a significant decrease of striatal
TH protein levels in IVIg-treated groups (vehicle and
MPTP) as compared with controls (Figure 6C,D).
Effects of MPTP and IVIg on nigral dopaminergic
neuronal loss
As expected, MPTP injections led to a significant decrease
in the number of TH-positive DAergic neurons in the
SNpc (Figure 7), as determined by immunohistochemistry.
Stereological count of TH-positive and cresyl-violet-
stained neurons in SNpc revealed a 33% reduction of TH-
positive neurons in the MPTP-control group, whereas
there was a 40% decrease in the MPTP-IVIg group
(Figure 7A), as compared with their respective controls.
The total number of SNpc neurons (TH-positive and
Figure 5 Lack of beneficial effects of intravenous immunoglobulin on depleted levels of dopamine and its metabolites. Catecholamines
and indolamine were quantified using HPLC in the striatum of mice. Concentrations of (A) dopamine (DA), (B) homovanillic acid (HVA), and (C)
3,4-dihydroxyphenylacetic acid (DOPAC) remained decreased following MPTP injections and subsequent intravenous immunoglobulin (IVIg)
treatment. (D) Concentration of serotonin. (A) to (D) Percentage of control values is indicated for significant variation (vehicle-control or vehicle-
IVIg, respectively). Two-way analysis of variance (ANOVA) also revealed lower (B) HVA and (D) serotonin levels in IVIg groups. Values represent
mean± standard error of the mean of 11 to 15 animals per group. Statistical analysis: one-way ANOVA followed by Tukey’s multiple comparison
test, ***P<0.001 control-MPTP versus control-vehicle, ###P<0.001 IVIg-MPTP versus IVIg-vehicle; two-way ANOVA analyses, ∞P<0.05 IVIg-treated
versus control-treated animals.
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cresyl-violet-stained) was also decreased by MPTP treat-
ment (Figure 7B). To verify whether IVIg treatment
affected the proportion of TH-positive neurons, we mea-
sured the ratio of TH-positive neurons versus total SNpc
cells, as identified with TH immunohistochemistry and
cresyl-violet staining (Figure 7C). Additionally, two-way
ANOVA analyses revealed that IVIg treatment led to sig-
nificant reductions in TH-positive neurons, total number of
SNpc neurons and the ratio of TH-positive versus total
SNpc neurons inmice.
Discussion
Our data clearly show that IVIg treatment has an im-
pact on various immune parameters in mice, confirming
the immunomodulatory action of IVIg in the periphery.
Indeed, systemic administration of IVIg led to the pres-
ence of human IgG at the surface of circulating leuko-
cytes, induced a significant decrease in the CD4+/CD8+
T-cell ratio and increased the Treg percentage. In the
present study, we have also assessed the state of the
brain DAergic system using a combination of validated
markers. However, our results suggest that immunomo-
dulating treatment with IVIg did not translate into neu-
rorestoration of the denervated nigrostriatal DAergic
pathway after an acute MPTP insult. Our observations
rather suggest potentially negative consequences of IVIg
treatment on certain components of the DAergic sys-
tem, as well as on the health status of the treated ani-
mals. The vast majority of preclinical studies aiming to
test new compounds for PD are tested in animal
Figure 6 Decreased tyrosine hydroxylase protein and dopamine transporter levels in the mouse striatum following MPTP treatment.
125I-RTI-121 specific binding to dopamine transporter (DAT) was measured with receptor binding autoradiography and showed a remarkable
decrease following MPTP treatment without any effect of intravenous immunoglobulin (IVIg). (A) Representative autoradiograms and (B)
quantification. Statistical analysis: mean± standard error of the mean (SEM; n= 11 to 15/group). One-way analysis of variance (ANOVA) followed
by Tukey’s multiple comparison test, ***P<0.001 control-MPTP versus control-vehicle, ###P<0.001 IVIg-MPTP versus IVIg-vehicle. Striatal tyrosine
hydroxylase (TH) protein level was also decreased following MPTP intoxication. (C) Representative Western blot of TH in MPTP-mice treated with
IVIg or vehicle. (D) Densitometric quantification of the Western blots. Data presented as mean± SEM (n= 11 to 15/group). Statistical analysis: one-
way ANOVA followed by Dunnett’s multiple comparison test. ***P<0.001, *P<0.05 versus control-vehicle. Besides the downregulating effect of
MPTP, a significant IVIg-induced decrease of TH in the striatum of mice was observed in vehicle-treated mice (*P<0.05 vs. control-vehicle) and
was further evidenced using two-way ANOVA analyses in both vehicle and MPTP groups (∞P<0.05 IVIg vs. control). Percentage of control values
is indicated for significant variation (vehicle-control vs. MPTP-control or vehicle-IVIg vs. MPTP-IVIg, respectively).
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models prior to the injury (for example, MPTP treat-
ment), thereby probing the neuroprotective properties
of the potential therapeutic agents. We opted instead
for a neurorestoration study design, in which the injec-
tions of IVIg began 20 hours after the last MPTP injec-
tion. MPTP-induced neurodegeneration is still ongoing
at that time, as DAergic denervation stabilizes approxi-
mately 7 days after initial MPTP insult [63-65]. Never-
theless, such post-MPTP treatment paradigm is more
compatible with an eventual clinical use of IVIg in
human PD, which would occur after the diagnosis,
when neurodegeneration processes are already engaged
[66].
Treg cell adoptive transfer has been previously
reported to protect from MPTP-induced nigrostriatal
denervation [57-59] in acute MPTP mouse models. In
these studies, the amount of Tregs needed to achieve
neurorestoration using adoptive transfer ranged between
0.5×106 and 3.5×106 injected into the tail vein 12 hours
following the last MPTP injection [57-59]. We also
observed a rise in Treg percentage among the CD4+
population, reaching up to 9% in the spleen of IVIg-
vehicle mice, after a 14-day treatment. However, this
increase in Tregs following IVIg administration did
not reach the 16 to 20% CD4+ Treg proportion previ-
ously reported [53,54]. Nevertheless, despite the sig-
nificant rise in peripheral Tregs, IVIg treatment did
not translate into measurable neurorestorative effects.
The lack of beneficial effects could be explained by
the fact that the rise in Tregs following the initiation
of IVIg treatment might have been too slow to allow
a sufficient exposure to Tregs to produce any benefits.
We also observed a significant increase of Treg per-
centage after MPTP administration with no additive
effects of IVIg. This is in accordance with Rosenkranz
and colleagues, who reported a higher suppressive ac-
tivity of Tregs in PD and AD patients and an
increased Treg number associated with aging [67]. Fi-
nally, Ramakrishna and colleagues associated the long-
term regulation of CNS inflammatory responses to the
induction of iCOS+CD4+ T cells [54], which were left
unchanged after the present IVIg treatment. The ab-
sence of neurorestorative effects of IVIg could thus
also be explained by the lack of expansion of the
iCOS+CD4+ T cells or the Treg population in the
MPTP-treated groups.
Figure 7 Quantification of nigral tyrosine hydroxylase-positive neurons following MPTP and intravenous immunoglobulin treatment.
Stereological counts of (A) tyrosine hydroxylase (TH)-positive dopaminergic (DAergic) neurons and (B) total DAergic neurons of the substantia
nigra pars compacta (SNpc) confirming that exposure to MPTP led to a significant nigral neurodegeneration. (C) Ratio of TH-positive versus total
SNpc neurons in the SNpc (n= 12 to 15 animals per group). (D) to (G) Low power photomicrograph representative of the state of the nigral
DAergic system following MPTP and intravenous immunoglobulin (IVIg) treatments. Scale bar: 150 μm. (D) Vehicle-control, (E) vehicle-IVIg, (F)
MPTP-control, (G) MPTP-IVIg. Statistical analysis: one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test, *P<0.05
control-MPTP versus control-vehicle, #P<0.05 IVIg-MPTP versus IVIg-vehicle. IVIg treatment (E), (G) resulted in a diminution in the number of TH-
positive neurons compared with vehicle-treated animals (D), (F), according to two-way ANOVA analyses (∞P<0.05; ∞∞P<0.01 IVIg vs. control).
Percentage of control values is indicated for significant variation (vehicle-control or vehicle-IVIg, respectively).
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Injections of IVIg resulted in a mild but significant de-
crease in the CD4+/CD8+ T-cell ratio. Such decreases
are also observed in IVIg-treated patients [68], suggest-
ing it may be a clinically relevant index of IVIg efficacy.
Interestingly, a significant decrease in CD4+/CD8+ ratio
is observed in PD patients as well [69-71], possibly
accounted for by an increased susceptibility to apoptosis
observed in CD4+ T cells, consequent of Fas overexpres-
sion [72]. IVIg has been reported to modulate the level
of expression of Fas and FasL and to inhibit FasL-
dependent apoptosis, in both in vivo and in vitro studies
[34,73-75]. This action of IVIg on the Fas/FasL pathway
could have been translated into neurorestoration. How-
ever, while being consistent with an immunoregulatory
action, the effect of IVIg on the CD4+/CD8+ T-cell ratio
was not associated with beneficial post-MPTP outcomes
on various DAergic markers.
The lack of efficacy of IVIg may also reflect the poor
CNS access owing to the presence of the blood–brain
barrier. However, our data rather suggest that IVIg dis-
played significant central bioavailability after systemic
administration. Indeed, a fraction of intraperitoneally
administered IVIg was detected in the striatum of trea-
ted mice using a specific ELISA, consistent with a previ-
ous report where peripherally administered IVIg was
also detected in APP/PS1 mouse brain using immuno-
histochemistry [76]. A number of studies have reported
data consistent with the penetration of a fraction of sys-
temically administered antibodies into brain tissues lead-
ing to central therapeutic effect [38,77,78]. Interaction
between Fc gamma receptor (FcγR) and immunoglobu-
lins is essential for the initiation of cellular and humoral
responses. In the CNS, FcγR are expressed on endothe-
lial cells, neurons, microglia, oligodendrocytes and astro-
cytes (as reviewed in [79]) and the IVIg migration to
critical regions of the brain, such as the striatum and
SNpc in PD, might act as a central immunomodulating
agent. A previous report showed that approximately 30%
of pigmented SNpc neurons were IgG-positive [80] in
PD patients but not in controls. This suggests that IgG
can access the brain during the course of the disease.
However, we found no increase in striatal IgG content in
MPTP-treated animals. The amount of human IgG
detected in the brain of treated mice suggests that low
central bioavailability is unlikely to be the sole reason for
the lack of efficacy of IVIg in restoring the DAergic
pathways.
After systemic injection, MPTP produces a reprodu-
cible lesion of the nigrostriatal DAergic pathway by
causing oxidative stress, mitochondrial damage and
neuronal cell death, as in idiopathic PD. Validation of
disease-modifying treatments before clinical trial initi-
ation is therefore often performed in MPTP-treated ro-
dent models [81,82]. However, these models are not
without important limitations [83]. First, the MPTP
model used here does not generate a massive degenera-
tion (−30 to 40% of TH-positive cells), which is required
for clinically detectable motor symptoms in humans
(−50 to 60%) [84,85]. This explains, at least in part, why
motor symptoms in the MPTP mouse model are insuffi-
ciently reliable for systematic assessment [83,86-89] and
were not evaluated here after IVIg treatment. To investi-
gate the symptomatic effects of IVIg, the use of the more
expensive MPTP monkey model should be considered
instead [83,90]. Second, the acute mouse MPTP model
does not replicate α-synucleinopathy or Lewy bodies,
which are pathognomonic of PD [91-93]. The use of
other models such as the chronic infusion MPTP models
or transgenic mice overexpressing human α-syn might
be helpful for these purposes [81,93-95]. Third, the re-
sponse of a mouse model to human IVIg may differ
from humans. Indeed, the absence of positive outcome
in our study might be the result of inadequate interac-
tions between human IgG and mouse FcγR, a hypothesis
only testable with the use of mouse IgG. However, given
that over 2,500 mice would have been required to gen-
erate the ~5 g IgG used in this study, murine IgG is
scarcely used in preclinical investigations. In a passive
model of idiopathic thrombocytopenic purpura, human
IVIg and purified mouse IgG shared the same kinetics to
restore platelet counts, thus validating the use of human
IVIg to study human therapy in mouse models [96].
Since monomeric human IVIg is well tolerated in mice,
mouse models of numerous diseases are now routinely
used to investigate its efficacy as well as its mechanisms
of action [35,53,97,98].
The unexpected deleterious effect of IVIg on TH ex-
pression is an intriguing observation that is particularly
challenging to explain. On the one hand, a plethora of
compounds such as nicotine, cannabinoid agonists and
progesterone receptor isoforms [99-101] have been shown
to modulate TH expression without obvious harmful
effects on the DAergic system. Similarly, our data sug-
gest that IVIg regulates TH expression at the protein or
RNA levels. On the other hand, the observed decrease in
striatal TH protein levels associated with a trend toward
decreased catecholamines, serotonin, nigral TH-positive
and total neurons can also be interpreted as a dele-
terious effect of IVIg on the murine DAergic system.
Although acute MPTP administration does not lead to
α-syn-positive nigral inclusions [91-93], α-syn-deficient
transgenic mouse models are more resistant to MPTP,
suggesting a possible implication of α-syn in the MPTP
toxicity [102-106]. Increased autoantibodies to α-syn
are present in the sera of PD patients [107,108], and
stereotactic injection of human IgG purified from the
sera of PD patients into mice SNpc produces a FcγR-
dependent microglial activation and a 40% TH-positive
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cell loss in the SNpc [109]. Since natural anti-α-syn anti-
bodies in IVIg preparations have been recently identified
[40], it is tempting to speculate that IVIg could have
modulated the nigrostriatal toxicity of MPTP by binding
to α-syn.
Conclusion
Despite the fact that current knowledge of IVIg mechan-
isms of action holds promising characteristics for the
treatment of PD, our results do not provide evidence of
a neurorestorative effect of IVIg treatment on the
nigrostriatal system of the MPTP-treated mouse. Our
data on the general health status, DAergic cell count,
TH protein levels and HVA striatal concentrations all
suggest that IVIg not only failed to generate beneficial
effects, but had a slight detrimental impact on the DAer-
gic system. Such possible harmful consequences flag the
need to proceed with caution before initiating clinical
trials in PD patients.
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